Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: A cohort study of 8486 primary-care patients

Diabetes and Metabolism

Volumn 39, Issue 4, 2013, Pages 306-313

  Bodegard, J ^a   Sundstrom J ^b   Svennblad, B ^b   Ostgren C J ^c   Nilsson, P M ^d   Johansson, G ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Cardiovascular disease mortality; Epidemiology; Type 2 diabetes; Weight control

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PRIMARY MEDICAL CARE; SUDDEN DEATH; SWEDEN; WEIGHT CHANGE;

CARDIOVASCULAR DISEASE MORTALITY; DIABÈTE DE TYPE 2; EPIDEMIOLOGY; ÉPIDÉMIOLOGIE; LA MORTALITÉ CARDIOVASCULAIRE; LE CONTRÔLE DU POIDS; TYPE 2 DIABETES; WEIGHT CONTROL;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84883782869     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.05.004     Document Type: Article

References (41)

1. Unick J.L., Beavers D., Jakicic J.M., Kitabchi A.E., Knowler W.C., Wadden T.A., et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 2011, 34:2152-2157.
2. Anderson J.W., Kendall C.W., Jenkins D.J. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331-339.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
4. Lean M.E., Powrie J.K., Anderson A.S., Garthwaite P.H. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990, 7:228-233.
5. Sjostrom L., Narbro K., Sjostrom C.D., Karason K., Larsson B., Wedel H., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
6. Reiter A. Weight loss does not lower heart disease risk from type 2 diabetes 2012, Department of Health and Human Services, U.S., [Available from: http://www.nih.gov/news/health/oct2012/niddk-19.htm].
7. Nilsson P.M. Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?. Diabetes Care 2008, Suppl. 2:S278-S283.
8. Doehner W., Erdmann E., Cairns R., Clark A.L., Dormandy J.A., Ferrannini E., et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol 2011.
9. Eeg-Olofsson K., Cederholm J., Nilsson P.M., Zethelius B., Nunez L., Gudbjornsdottir S., et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009, 52:65-73.
10. Ostgren C.J., Sundstrom J., Svennblad B., Lohm L., Nilsson P.M., Johansson G. Associations of HbA and educational level with risk of cardiovascular events in 32 871 drug-treated patients with type 2 diabetes: a cohort study in primary care. Diabet Med 2013.
11. Lidman B., Linder R. Working Model Stockholm http://www.pygargus.se/3_en.html.
12. Martinell M., Stalhammar J., Hallqvist J. Automated data extraction-a feasible way to construct patient registers of primary care utilization. Ups J Med Sci 2012, 117:52-56.
13. Kjeldsen S.E., Stalhammar J., Hasvold P., Bodegard J., Olsson U., Russell D. Effects of losartan versus candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010, 24:263-273.
14. Fonseca V., McDuffie R., Calles J., Cohen R.M., Feeney P., Feinglos M., et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013.
15. Ludvigsson J.F., Andersson E., Ekbom A., Feychting M., Kim J.L., Reuterwall C., et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011, 11:450.
16. Shrier I., Platt R.W. Reducing bias through directed acyclic graphs. BMC Medical Res Methodol 2008, 8:70.
17. Lin D.Y., Psaty B.M., Kronmal R.A. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998, 54:948-963.
18. Ekstrom N., Miftaraj M., Svensson A.M., Andersson Sundell K., Cederholm J., Zethelius B., et al. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 2012, 14:717-726.
19. Social T.O. Tobacco 2010, Directorate General Health and Consumers, Brussels.
20. Goudswaard A.N., Furlong N.J., Rutten G.E., Stolk R.P., Valk G.D. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004, CD003418.
21. Jacober S.J., Scism-Bacon J.L., Zagar A.J. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006, 8:448-455.
22. Balena R., Hensley I.E., Miller S., Barnett A.H. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2012.
23. Luis Bautista J., Bugos C., Dirnberger G., Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2003, 25:194-209.
24. Rosenstock J., Hassman D.R., Madder R.D., Brazinsky S.A., Farrell J., Khutoryansky N., et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004, 27:1265-1270.
25. Saloranta C., Hershon K., Ball M., Dickinson S., Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002, 87:4171-4176.
26. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
27. Chiasson J.L., Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001, 24:989-994.
28. Hanefeld M., Brunetti P., Schernthaner G.H., Matthews D.R., Charbonnel B.H. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27:141-147.
29. Pavo I., Jermendy G., Varkonyi T.T., Kerenyi Z., Gyimesi A., Shoustov S., et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:1637-1645.
30. Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89:6068-6076.
31. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012, 35:731-737.
32. Droyvold W.B., Lund Nilsen T.I., Lydersen S., Midthjell K., Nilsson P.M., Nilsson J.A., et al. Weight change and mortality: the Nord-Trondelag Health Study. J Intern Med 2005, 257:338-345.
33. Mikkelsen K.L., Heitmann B.L., Keiding N., Sorensen T.I. Independent effects of stable and changing body weight on total mortality. Epidemiology 1999, 10:671-678.
34. Nilsson P.M., Nilsson J.A., Hedblad B., Berglund G., Lindgarde F. The enigma of increased non-cancer mortality after weight loss in healthy men who are overweight or obese. J Intern Med 2002, 252:70-78.
35. Sorensen T.I., Rissanen A., Korkeila M., Kaprio J. Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities. PLoS Med 2005, 2:e171.
36. Williamson D.F., Thompson T.J., Thun M., Flanders D., Pamuk E., Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
37. Caterson I.D., Finer N., Coutinho W., Van Gaal L.F., Maggioni A.P., Torp-Pedersen C., et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabet Obes Metab 2012, 14:523-530.
38. van Dieren S., Czernichow S., Chalmers J., Kengne A.P., de Galan B.E., Poulter N., et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabet Obes Metab 2012, 14:464-469.
39. Aubin H.J., Farley A., Lycett D., Lahmek P., Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ 2012, 345:e4439.
40. Canga N., De Irala J., Vara E., Duaso M.J., Ferrer A., Martinez-Gonzalez M.A. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care 2000, 23:1455-1460.
41. Persson L.G., Hjalmarson A. Smoking cessation in patients with diabetes mellitus: results from a controlled study of an intervention programme in primary healthcare in Sweden. Scand J Prim Health Care 2006, 24:75-80.